Crossmark

The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial

Crossref DOI link: https://doi.org/10.1007/s00228-026-04050-6

Published Online: 2026-05-14

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abdelkader, Asmaa M.

Osama, Hasnaa

Hassan, Eman S.

Alsfouk, Bshra A.

Elmasry, Thanaa A.

Elkhashab, Khaled

Hussein, Raghda R.S.

Kamal, Marwa
License Information

Text and Data Mining valid from 2026-05-14

Version of Record valid from 2026-05-14
More Information

Article History

Received: 8 November 2025

Accepted: 2 April 2026

First Online: 14 May 2026

Change Date: 19 May 2026

Change Type: Update

Change Details: 4th author affiliation correction

Declarations

:

: Informed consent was secured from all study participants.

: After assessing the study protocol for ethical and academic concerns, the Institutional Review Board of the Faculty of Medicine, Fayoum University, made the necessary amendments and granted approval.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below